Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2025 Report on Business magazine’s sixth annual Women Lead Here ...
Copyright 2025 The Associated Press. All Rights Reserved.
Dr. Dukes has held leadership roles in public and private biopharmaceutical companies, leveraging vast experience in ...
Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...
Ke’won Parker is considered armed and dangerous, according to the Cumberland County Sheriff’s Office. He is considered a ...
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...
When the Grizzlies announced Friday morning that they'd fired coach Taylor Jenkins, the NBA world had a pretty consistent ...
The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...
Harrow, Inc. offers speculative gains from $20s to $30s, with Q4 growth, bullish 2025 revenue guidance, and long-term growth ...
Stocktwits on MSN5h
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveShares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
The Memphis Grizzlies fired Taylor Jenkins, their winningest coach, on Friday with the team struggling down the stretch and ...
Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 61.33%, which has investors questioning if this is right time to buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback